Skip to content

AnaptysBio, Inc. ANAB Change in Other Assets

Change in Other Assets at other companies

Eli Lilly logo
Eli LillyLLY
$1.65B+98.4%
Pfizer logo
PfizerPFE
-$322.25M+61.9%
Amgen logo
AmgenAMGN
-$8M-104%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$2.33M+21.9%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$1.74M+124%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$155K-102%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.73B+180%
Enterprise value$1.48B+176%
P/S7.4×+1.9×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about AnaptysBio, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AnaptysBio, Inc.'s change in other assets?
AnaptysBio, Inc. (ANAB) reported change in other assets of -$1.5M in Q1 2026.
How has AnaptysBio, Inc.'s change in other assets changed year-over-year?
AnaptysBio, Inc.'s change in other assets decreased by 183.2% year-over-year, from -$530K to -$1.5M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.